Impact of Bevacizumab on parenchymal damage and functional recovery of the liver in patients with colorectal liver metastases

Little is known about the safety of the anti-VEGF antibody bevacizumab in patients undergoing resection for colorectal liver metastases (CLM). This meta-analysis evaluates the impact of bevacizumab on parenchymal damage and functional recovery in patients undergoing resection for CLM.